apoaequorin
recombinant calcium binding protein; component of aequorin
Networked: 3
relevant articles (0 outcomes,
1 trials/studies)
Bio-Agent Context: Research Results
Experts
1. | Ehlers, Vanessa L:
1 article
(11/2020)
|
2. | Moyer, James R:
1 article
(11/2020)
|
3. | Smies, Chad W:
1 article
(11/2020)
|
4. | Bauter, Mark R:
1 article
(07/2013)
|
5. | Marone, Palma Ann:
1 article
(07/2013)
|
6. | Moran, Daniel L:
1 article
(07/2013)
|
7. | Soni, Madhu G:
1 article
(07/2013)
|
8. | Furuichi, Takuya:
1 article
(05/2004)
|
9. | Goh, Tatsuaki:
1 article
(05/2004)
|
10. | Higashi, Katsumi:
1 article
(05/2004)
|
Related Diseases
1. | Body Weight (Weight, Body)
07/01/2013
- " For this study, Sprague-Dawley (Hsd:SD) rats (10/sex/group) were administered via oral gavage 0 (control), 92.6, 462.9, and 926.0mg/kg body weight (bw)/day of Apoaequorin preparation, for 90 days. " 07/01/2013
- " There were no clinical or ophthalmological signs, body weight, body weight gain, food consumption, food efficiency, clinical pathology or histopathological changes attributable to administration of Apoaequorin. "
|
2. | Shock
|
3. | Ischemia
|
|
Related Drugs and Biologics